{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:54:18Z","timestamp":1761929658674},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejca.2013.03.029","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T21:23:44Z","timestamp":1368912224000},"page":"2461-2468","source":"Crossref","is-referenced-by-count":6,"title":["Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00359359","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas Christoph","family":"Gauler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Christian","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Frickhofen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gonschorek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Giurescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried Ernst Erich","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2013.03.029_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.ejca.2013.03.029_b0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/JTO.0b013e31815bdc0d","article-title":"The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer","volume":"2","author":"Shepherd","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.029_b0015","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1200\/JCO.1999.17.6.1794","article-title":"Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress","volume":"17","author":"Chute","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.029_b0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive stage small-cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.029_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.029_b0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/JTO.0b013e3181d95c87","article-title":"A meta-analysis of randomized controlled trials comparing irinotecan\/platinum with etoposide\/platinum in patients with previously untreated extensive-stage small cell lung cancer","volume":"5","author":"Jiang","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2013.03.029_b0035","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2006.08.4145","article-title":"Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301","volume":"24","author":"Onoda","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2013.03.029_b0040","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2009.26.7682","article-title":"Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer","volume":"28","author":"Ettinger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.029_b0045","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.029_b0050","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161212800626238","article-title":"Novel drugs targeting microtubules: the role of epothilones","volume":"18","author":"Ferrandina","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2013.03.029_b0055","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/annonc\/mdq780","article-title":"A phase-II trial two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer","volume":"22","author":"Rustin","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.03.029_b0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/bjc.2011.499","article-title":"Phase I\/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer","volume":"106","author":"McMeekin","year":"2012","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.029_b0065","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/sj.bjc.6605931","article-title":"Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma","volume":"103","author":"DeConti","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.03.029_b0070","first-page":"26","article-title":"Phase-II trial of the epothilone analog sagopilone (ZK-EPO) in patients with recurrent glioblastoma: initial reports of the EORTC study 25061","author":"Stupp","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.029_b0075","first-page":"53786568","article-title":"Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non small cell lung cancer","author":"Gatzemeier","year":"2007","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.029_b0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cllc.2011.02.005","article-title":"Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance","volume":"13","author":"Edelman","year":"2012","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.029_b0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1215\/15228517-2008-072","article-title":"Sagopilone crosses the blood\u2013brain barrier in vivo to inhibit brain tumor growth and metastases","volume":"11","author":"Hoffmann","year":"2009","journal-title":"Neuro Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2013.03.029_b0090","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","article-title":"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006","volume":"24","author":"Kris","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.029_b0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","article-title":"Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors","volume":"21","author":"Schmid","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2013.03.029_b0100","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.bjc.6605327","article-title":"Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial","volume":"101","author":"Arnold","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.03.029_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.03.029_b0110","first-page":"12","article-title":"Randomized trial of ixabepilone plus carboplatin or paclitaxel plus carboplatin in \u00df3 Tubulin overexpressing non-small-cell lung cancer","volume":"5","author":"Edelman","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2013.03.029_b0115","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1345\/aph.1M005","article-title":"The epothilones: how pharmacology relates to clinical utility","volume":"43","author":"Michaud","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejca.2013.03.029_b0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-12-355","article-title":"Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial","volume":"12","author":"Ghoreishi","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2013.03.029_b0125","first-page":"29","article-title":"Results from a randomized phase-II study to evaluate the safety and efficacy of acetyl-l-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON)","author":"Lhomme","year":"2011","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2013.03.029_b0130","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1200\/JCO.2005.03.0981","article-title":"Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors","volume":"23","author":"Rubin","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2013.03.029_b0135","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1158\/1078-0432.CCR-06-1653","article-title":"A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer","volume":"13","author":"Forster","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.ejca.2013.03.029_b0140","doi-asserted-by":"crossref","first-page":"10197","DOI":"10.1158\/0008-5472.CAN-08-2091","article-title":"Molecular mechanisms of patupilone resistance","volume":"68","author":"Mozzetti","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.03.029_b0145","first-page":"23","article-title":"A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small-cell lung cancer","author":"Yee","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T23:25:59Z","timestamp":1539645959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0959804913002980"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.03.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}